[HTML][HTML] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
…, F Cervantes, JJ Cornelissen… - … England Journal of …, 2003 - Mass Medical Soc
Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had …
[HTML][HTML] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
…, P Rousselot, J Reiffers, JJ Cornelissen… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
[HTML][HTML] Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
…, H Endeman, DA Gommers, JJ Cornelissen… - Nature …, 2021 - nature.com
Key questions in COVID-19 are the duration and determinants of infectious virus shedding.
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …
Here, we report that infectious virus shedding is detected by virus cultures in 23 of the 129 …
Human fetal lymphoid tissue–inducer cells are interleukin 17–producing precursors to RORC+ CD127+ natural killer–like cells
…, K Weijer, JL Grogan, WE Fibbe, JJ Cornelissen… - Nature …, 2009 - nature.com
The human body contains over 500 individual lymph nodes, yet the biology of their formation
is poorly understood. Here we identify human lymphoid tissue–inducer cells (LTi cells) as …
is poorly understood. Here we identify human lymphoid tissue–inducer cells (LTi cells) as …
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
…, B Chapuis, R Chopra, JJ Cornelissen… - Blood, The Journal …, 2000 - ashpublications.org
Peripheral blood cells are increasingly used in place of bone marrow as a source of hematopoietic
stem cells for allogeneic transplantation. The relative efficacy of these 2 approaches …
stem cells for allogeneic transplantation. The relative efficacy of these 2 approaches …
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …
JJ Cornelissen, WLJ Van Putten, LF Verdonck… - Blood, 2007 - ashpublications.org
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical
Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (…
Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (…
Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients
…, JC Fockens, JJ Cornelissen… - The Journal of …, 2003 - academic.oup.com
During a 17-month period, we performed retrospective analyses of the prevalence of and
clinical symptoms associated with human metapneumovirus (hMPV) infection, among patients …
clinical symptoms associated with human metapneumovirus (hMPV) infection, among patients …
Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell …
…, B Löwenberg, JJ Cornelissen - Blood, The Journal …, 2002 - ashpublications.org
Recipients of a partially T-cell–depleted (TCD) allogeneic stem cell transplantation (allo-SCT)
developing reactivation of Epstein-Barr virus (EBV) with quantified viral DNA levels …
developing reactivation of Epstein-Barr virus (EBV) with quantified viral DNA levels …
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk… - Nature reviews Clinical …, 2012 - nature.com
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent …
Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted …
…, B Löwenberg, JJ Cornelissen - Blood, The Journal …, 2000 - ashpublications.org
We evaluated the efficacy, toxicity, and outcome of preemptive ganciclovir (GCV) therapy in
80 cytomegalovirus (CMV)-seropositive patients allografted between 1991 and 1996 and …
80 cytomegalovirus (CMV)-seropositive patients allografted between 1991 and 1996 and …